Clinical Trials

Phase 1 Active not recruiting

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT01479842 2026-03-23

Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma

48 enrolled

Phase 4 Not yet recruiting

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT07474961 2026-03-16

BLOOD-dose

400 enrolled

LymphoidPlasma cell

Waldenstrom Macroglobulinemia, Multiple Myeloma

NCT03506373 2026-03-05

Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia

Phase 2 Terminated

21 enrolled 11 charts

Phase 2 Active not recruiting

Waldenstrom Macroglobulinemia

NCT03620903 2025-12-05

Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia

53 enrolled

Phase 1 Not yet recruiting

Waldenstrom Macroglobulinemia

NCT07169565 2025-09-11

Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia

21 enrolled

Phase 2 Active not recruiting

Waldenstrom Macroglobulinemia

NCT04273139 2025-07-30

Ibrutinib + Venetoclax in Untreated WM

45 enrolled 15 charts

Waldenstrom Macroglobulinemia

NCT04042376 2025-05-25

A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM)

Phase 4 Completed

17 enrolled 15 charts

Waldenstrom Macroglobulinemia

NCT04062448 2025-05-25

A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)

16 enrolled 14 charts

Phase 2 Active not recruiting

Waldenstrom Macroglobulinemia

NCT04263480 2025-04-04

CZAR-1

99 enrolled

201 enrolled 19 charts 2 FDA

Waldenstrom Macroglobulinemia, Neoplasms

NCT03053440 2024-10-26

ASPEN

Phase 3 Completed

Waldenstrom Macroglobulinemia

NCT04274738 2024-08-27

A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4

16 enrolled

Waldenstrom Macroglobulinemia

NCT04061512 2024-05-10

RAINBOW

Phase 2/3 Recruiting

148 enrolled

Waldenstrom Macroglobulinemia

NCT03225716 2024-05-03

A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia

Phase 1 Terminated

13 enrolled 13 charts

Waldenstrom Macroglobulinemia

NCT02332980 2024-01-03

Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas

65 enrolled 21 charts

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT03679624 2023-10-23

Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia

Phase 2 Terminated

1 enrolled 8 charts

Hypergammaglobulinemia, Waldenstrom Macroglobulinemia, Recurrence

NCT04522284 2023-03-29

PRECISE CURATE.AI Pilot Clinical Trial

Phase 1/2 Unknown

20 enrolled

Waldenstrom Macroglobulinemia, Neoplasms

NCT02604511 2022-12-07

Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing

31 enrolled 12 charts

Waldenstrom Macroglobulinemia

NCT04665115 2022-08-03

Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)

Phase 2 Withdrawn

Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02165397 2021-03-03

Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia

Phase 3 Completed

181 enrolled 20 charts

Lymphoma, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia

NCT01109069 2020-05-27

Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia

199 enrolled 14 charts

Burkitt Lymphoma, Leukemia, Lymphoid, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT04043845 2020-02-05

ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies

Phase 1 Withdrawn

Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01614821 2020-01-21

Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia

63 enrolled 12 charts

Waldenstrom Macroglobulinemia, Recurrence

NCT02950220 2019-07-30

Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

2 enrolled

Burkitt Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02991638 2018-04-12

Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers

Phase 3 Unknown

62 enrolled

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Hepatitis B, Chronic, Lymphoma, Mantle-Cell

NCT02381080 2017-06-26

Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy

26 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02109224 2015-08-20

Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection

Phase 1 Terminated

72 enrolled

Multi-centric Castleman's Disease, Burkitt Lymphoma, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, HIV Infections, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Intraocular Lymphoma

NCT00849654 2013-05-22

PCYC-04753

66 enrolled